Histoplasmosis in Solid Organ Transplantation

Area of Science:

• Medical Mycology
• Infectious Diseases
• Transplant Medicine

Background:

• Histoplasma capsulatum is a dimorphic fungus causing histoplasmosis.
• While typically self-resolving in immunocompetent individuals, it presents a higher risk for solid organ transplant (SOT) recipients.
• SOT recipients face increased risk of symptomatic disease and dissemination.

Purpose of the Study:

• To review the pathogenesis, epidemiology, clinical manifestations, and management of histoplasmosis.
• To highlight the specific challenges and considerations for SOT recipients.
• To provide a comprehensive overview for clinicians managing this population.

Main Methods:

• Literature review focusing on Histoplasma capsulatum in SOT recipients.
• Synthesis of information on diagnosis, treatment, and outcomes.
• Analysis of epidemiological trends and risk factors.

Main Results:

• Histoplasmosis diagnosis in SOT recipients relies on direct pathogen observation or detection of antigens, antibodies, or nucleic acids.
• All SOT recipients with histoplasmosis require treatment.
• Treatment choice and duration are guided by disease severity.

Conclusions:

• Histoplasmosis is a serious concern in SOT recipients, with potential for extrapulmonary dissemination.
• Early diagnosis and appropriate antifungal therapy are essential for favorable outcomes.
• Management strategies must be individualized based on clinical presentation and disease severity.